Michelle Gilson
Stock Analyst at Morgan Stanley
(1.07)
# 3,898
Out of 5,131 analysts
31
Total ratings
32.14%
Success rate
-6.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $5.92 | +237.84% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $37.36 | -19.70% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $2.51 | +577.29% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $208.76 | -6.11% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $34.10 | +31.96% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $29.42 | +158.33% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $57.71 | +57.68% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $5.92
Upside: +237.84%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $37.36
Upside: -19.70%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $2.51
Upside: +577.29%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $208.76
Upside: -6.11%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $34.10
Upside: +31.96%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $29.42
Upside: +158.33%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $57.71
Upside: +57.68%